Deutsche Bank lowered the firm’s price target on Labcorp to $240 from $265 and keeps a Hold rating on the shares post the Q1 results. The analyst says drug development headwinds offset the "solid" base business.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LH: